Osimertinib, the first-approved third-generation EGFR inhibitor, facilitates SREBP1 degradation and reduces the levels of its targets and lipogenesis in EGFR-mutant NSCLC cells and tumors, which suggests an effective strategy for overcoming acquired resistance of EGFR inhibitors by targeting SREBP-1 (144). Here, SREBF1 is linked to non-small cell lung carcinoma.